Engineering oncolytic measles virus to circumvent the intracellular innate immune response. - Wikidata - awgldk - TriplyDB

Engineering oncolytic measles virus to circumvent the intracellular innate immune response.

Engineering oncolytic measles virus to circumvent the intracellular innate immune response.

http://www.wikidata.org/entity/Q37324179

about

Systemic delivery of oncolytic viruses: hopes and hurdles New viruses for cancer therapy: meeting clinical needs Enhancement of oncolytic properties of recombinant newcastle disease virus through antagonism of cellular innate immune responses Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade From scourge to cure: tumour-selective viral pathogenesis as a new strategy against cancer Measles virus entry through the signaling lymphocyte activation molecule governs efficacy of mantle cell lymphoma radiovirotherapy.Infection and killing of multiple myeloma by adenoviruses Enhanced antitumor effects of an engineered measles virus Edmonston strain expressing the wild-type N, P, L genes on human renal cell carcinoma Viral oncolysis - can insights from measles be transferred to canine distemper virus?Impact of tumor microenvironment on oncolytic viral therapy Oncolytic Viruses for Cancer Therapy: Overcoming the Obstacles.Systemic therapy of disseminated myeloma in passively immunized mice using measles virus-infected cell carriers.Success of measles virotherapy in ATL depends on type I interferon secretion and responsiveness.Engineered measles virus Edmonston strain used as a novel oncolytic viral system against human hepatoblastoma.Gene therapy progress and prospects cancer: oncolytic viruses.Attenuated oncolytic measles virus strains as cancer therapeutics Deficiency of caspase 3 in tumor xenograft impairs therapeutic effect of measles virus Edmoston strain.The Impact of Macrophage- and Microglia-Secreted TNFα on Oncolytic HSV-1 Therapy in the Glioblastoma Tumor Microenvironment Attenuation of V- or C-defective measles viruses: infection control by the inflammatory and interferon responses of rhesus monkeys.CD8(+) T-cell Immune Evasion Enables Oncolytic Virus Immunotherapy Vesicular stomatitis virus as a treatment for colorectal cancer Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis.Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded.Oncolytic measles virus strains as novel anticancer agents.Measles virus for cancer therapy.Pharmacologic and chemical adjuvants in tumor virotherapy.The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon.Engineering oncolytic viruses to exploit tumor specific defects in innate immune signaling pathways.Differential cellular immune responses to wild-type and attenuated edmonston tag measles virus strains are primarily defined by the viral phosphoprotein gene.Use of attenuated paramyxoviruses for cancer therapy.Replicating viral vectors for cancer therapy: strategies to synergize with host immune responses.Oncolytic virotherapy Antiglioma oncolytic virotherapy: unattainable goal or a success story in the making?Enhancing the Oncolytic Activity of CD133-Targeted Measles Virus: Receptor Extension or Chimerism with Vesicular Stomatitis Virus Are Most Effective Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects.Advances in systemic delivery of anti-cancer agents for the treatment of metastatic cancer.Advances in the design and development of oncolytic measles viruses.Measles virus causes immunogenic cell death in human melanoma.Oncolytic viruses from the perspective of the immune system.Selective replication of oncolytic virus M1 results in a bystander killing effect that is potentiated by Smac mimetics.

P2860

Q21284969-430F3945-80FC-4538-8CD8-2454A9274A3A Q24567699-6DC53110-0A1F-4AA1-8CB1-D336F8039D59 Q24631361-93B859B4-5B0A-43B0-9FF4-64F552265580 Q26769977-B7253196-71B1-41C7-B811-142231191BFF Q26822694-257329FB-8E56-4DE6-B91F-DA4236A8048E Q30557338-D18CAFED-950E-4A45-8988-6CEF11063EEE Q33691833-6943E5BD-E9DA-493F-95FB-1036C329A41F Q33731148-3601B6A5-F6AB-491E-88D4-E4093E6A4FAA Q33820717-1FA9441C-5110-46A2-8F55-C6A622276BF4 Q33895533-3D5BBED1-ACD5-466A-BF86-459D6FE4AF56 Q33906116-8A0E85F6-FB31-489B-ADD4-D78E0C4FD0EB Q33930081-2696F0B2-7BD0-4621-AB7D-931B5F9EC2FA Q34053730-39C72F07-68D1-493B-A30C-2858B3029D48 Q34421151-A5144DDA-2955-434E-9B92-888C13D40D88 Q34770611-AEA5D0DD-C7A4-48D2-A428-E0358DBE5FBE Q35818876-E2BB0E21-3EDE-4026-8F5D-1A4F70942C1B Q36140704-850FBF91-C747-418F-ADD5-02D414672DA3 Q36658280-023F1D3B-EF9D-449E-A39F-56D054A55EBE Q36673332-2E989D93-4981-41EF-A09F-EB8D752A00F0 Q36753953-D85A8A9D-A732-441E-9744-2CF28538E399 Q36928614-2CD148FE-0317-4816-B024-C3F6BC46EECE Q36937117-60BB7026-EEEF-405A-9CEC-8FEBFF07ED70 Q37191007-ECB4A30C-6088-46A4-88B8-E7B806D5A203 Q37261017-738CC237-D72E-4605-A3E7-FCC066DF76D5 Q37388577-16D747BC-7597-4E06-8BF8-A5E266AE5F26 Q37492540-CFB46892-4B05-4CD1-BFA1-FB8F7468FA87 Q37561072-97C91C99-9634-4AC4-845B-8822CA55B3CF Q37564490-395A59B8-CDA6-4F5F-8D7F-DEE63F20CBF2 Q37583896-18F68254-880D-440B-8DF9-455A2C112505 Q37810599-56E97B8C-84DE-4DF8-A4DD-6C76EE444D63 Q37933439-846C4B08-CF67-42DF-B580-B4107AE5CDEA Q38025263-46F11278-4691-4B68-A3A9-B171491E656A Q38218674-05B31519-1557-44C1-8A29-5C96B91DF6CF Q38685020-4532276F-AB2D-4BB2-A66C-E62FEBA991AD Q38754467-BCDAC948-1424-43C0-A0A7-96D7A098A2F9 Q38808823-E9C20172-4195-4437-8D82-56E5218F5575 Q38924566-13DEC35B-F92C-4706-9974-F94839FF1E76 Q39428453-A532E4B6-FDDE-4578-8904-4B55BD6E03B7 Q39974038-36A8A12A-CB36-4D5B-B431-F2CDE0602557 Q40162604-6E6E4C31-73BD-48F5-BC10-AF1D7D17C2CC

P2860

Engineering oncolytic measles virus to circumvent the intracellular innate immune response.

http://www.wikidata.org/entity/Q37324179

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 16 January 2007

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Engineering oncolytic measles ...... llular innate immune response.

@en

Engineering oncolytic measles ...... llular innate immune response.

@nl

type

label

Engineering oncolytic measles ...... llular innate immune response.

@en

Engineering oncolytic measles ...... llular innate immune response.

@nl

prefLabel

Engineering oncolytic measles ...... llular innate immune response.

@en

Engineering oncolytic measles ...... llular innate immune response.

@nl

P1433

Q37324179-AAECA435-559E-434A-8BA5-7DB75C46FFBF

P1476

Q37324179-DEDFFA51-75FF-4BBF-9470-505D31A4B00A

P2093

Q37324179-C198B238-C6C3-4BBF-B323-146008AB74F1

Q37324179-D8CF6A87-1D16-428B-8994-9E1BAA147A96

Q37324179-EC4EB122-3004-4182-A56E-70AC88905EDD

P2860

Q37324179-214ADC0E-E09C-4A9B-BAFC-6D30A0337A13

Q37324179-2EC541AE-9D70-42A7-957F-49013A49CCAF

Q37324179-2F042C41-03AA-4E08-8607-1A5D5375D48A

Q37324179-344522AF-A28C-4EF9-9783-BBC24822A07E

Q37324179-38DE53EB-898A-47AD-AAB8-CBA1003473FA

Q37324179-38FC9498-2E1C-413A-832C-7CAE4E359EC0

Q37324179-3C0837A1-147B-4C5D-A776-9611FB90DC51

Q37324179-3CBB2306-453C-4F36-90A7-0E155BAD74C7

Q37324179-3F15CF39-2CE1-47EE-BEF6-7036C9351F23

Q37324179-4C64A182-DD41-4859-8EF3-3EF2AC46BB3C

P304

Q37324179-7B8E1633-7642-4BBC-8A7C-22492AA5BC67

P31

Q37324179-2BF7AE56-54D7-4B3E-ADF4-9AE09F72D454

P356

Q37324179-BD53E028-FD80-4F43-8952-EB69676997E1

P433

Q37324179-903E5F76-234B-44B2-AAF3-4F59A69C0AC3

P478

Q37324179-8902FE33-C2AB-4A5D-B077-ED4634D29A12

P50

Q37324179-12C8276B-7556-4A9E-A8F6-AB57768E4EC6

Q37324179-4095D44C-60A3-4321-9E91-5F70960AF576

Q37324179-7F5EB265-E45A-4EE1-8398-696F57BEC5ED

P577

Q37324179-45EA9E78-E4BE-48C8-AD3F-46704CE68883

P5875

Q37324179-51EED286-9C7B-4602-891D-834BC39AC0F5

P698

Q37324179-784AE2AB-E13A-4D26-A1D2-105268D62728

P921

Q37324179-8CC5010F-D36E-4ACC-8C29-94000508E47F

Q37324179-F9B48402-EFCB-4538-A272-F696C9B2DE5C

P932

Q37324179-448DABC2-88B9-4606-8D30-AB52282BF7B9

P356

P1433

Molecular Therapy

P1476

Engineering oncolytic measles ...... llular innate immune response.

@en

P2093

Ianko Iankov

http://www.w3.org/2001/XMLSchema#string

Kosei Hasegawa

http://www.w3.org/2001/XMLSchema#string

Mary Harvey

http://www.w3.org/2001/XMLSchema#string

P2860

The V proteins of paramyxoviruses bind the IFN-inducible RNA helicase, mda-5, and inhibit its activation of the IFN-beta promoter

SLAM (CDw150) is a cellular receptor for measles virus

The paramyxovirus simian virus 5 V protein slows progression of the cell cycle.

Recovery of pathogenic measles virus from cloned cDNA

Evasion of host defenses by measles virus: wild-type measles virus infection interferes with induction of Alpha/Beta interferon production.

Observation of measles virus cell-to-cell spread in astrocytoma cells by using a green fluorescent protein-expressing recombinant virus.

Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus.

VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents.

Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter.

Paramyxovirus accessory proteins as interferon antagonists.

P304

588-597

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.MT.6300076

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P50

Stephen J Russell

Iana H Haralambieva

P577

2007-01-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6558565

http://www.w3.org/2001/XMLSchema#string

P698

17245355

http://www.w3.org/2001/XMLSchema#string

P921

oncolytic virus

P932

3833616

http://www.w3.org/2001/XMLSchema#string